Takeda Pharmaceutical (TAK) catalysts

Upcoming FDA decisions and readouts we track for Takeda Pharmaceutical, each with the filing that announced it.

Listed on — NYSE Catalysts tracked — 1 Rows last checked — 07 Oct 2026

FreeBioList tracks 1 upcoming catalyst for Takeda Pharmaceutical (TAK, listed on NYSE). It concerns Zasocitinib (TAK-279) (Moderate-to-severe plaque psoriasis).

First on the list: the PDUFA date for Zasocitinib (TAK-279) (Moderate-to-severe plaque psoriasis), guided by the company to Q1 2027.

The row links to an SEC filing (8-K or 6-K). It has been verified by a person reading the filing itself, most recently on 07 Oct 2026. The methodology page explains each status.

Background reading: What a PDUFA date is, and why the FDA doesn't publish them.

Ticker: TAK
Next catalyst: Q1 2027
Type: PDUFA date
Listed options: Yes

Company ▾	Drug ▾	Effect / indication	Next catalyst ▾	Phase / type ▾	Status ▾	Source	Options
Takeda Pharmaceutical TAK · NYSE	Zasocitinib (TAK-279)	Moderate-to-severe plaque psoriasis	Q1 2027 company guidance	PDUFA date	Verified	6-K ↗	Yes
Notes — Filing states the FDA accepted the NDA under Priority Review and "The Prescription Drug User Fee Act (PDUFA) target action date is in the first quarter of calendar year 2027". No exact day disclosed. Source: 6-K, filed 14 Sep 2026 · verified 07 Oct 2026

Companies working on related conditions

Alumis (ALMS)Plaque psoriasis (TYK2 inhibitor); Plaque psoriasis
Vanda Pharmaceuticals (VNDA)Generalised pustular psoriasis

Also due in Q1 2027

Pharming Group (PHAR)PDUFA date for Leniolisib (Joenja) lower doses, 30 Jan 2027
Belite Bio (BLTE)PDUFA date for Tinlarebant, 12 Feb 2027
Arcutis Biotherapeutics (ARQT)PDUFA date for ZORYVE (roflumilast) cream 0.05%, 23 Feb 2027
Unicycive Therapeutics (UNCY)PDUFA date for Oxylanthanum carbonate (OLC), Mar 2027 (expected)
Intellia Therapeutics (NTLA)PDUFA date for Lonvoguran ziclumeran (lonvo-z), 10 Mar 2027
Apnimed (APMD)PDUFA date for AD109 (Oxnimbi), 28 Feb 2027